Toronto – – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) replaced its chief financial officer effective immediately, promoting Corporate Controller Matthew Sobczyk to Interim CFO after Rashed Dewan stepped down from the role.

Sobczyk, a 2020 hire, takes over the finance function

Sobczyk first joined the interventional MRI (iMRI) company in 2020 and moves up from Corporate Controller. The company did not name a permanent successor or give a timeline for a CFO search.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has introduced new Treatment Delivery Console (TDC) software that it says provides a roadmap for surgeons to perform up to six TULSA Procedures per system per day, up from a reported maximum of four among a few physicians today.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has appointed Richard Fabian, a medical imaging executive with more than 29 years of experience, as President, effective immediately, as the company moves its previous President into a newly created Chief Technology Officer role.

Toronto – October 12, 2026 -- Profound Medical Corp. expects third-quarter 2026 revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.

Revenue nearly doubles year over year and almost quadruples sequentially

The preliminary, unaudited range implies growth of approximately 85% to 89% from $5.3 million in the third quarter of 2025. Compared with $2.5 million in the second quarter of 2026, revenue is expected to rise approximately 292% to 300%.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV), ending a dual listing it says no longer justifies its cost. The company will keep its primary listing on Nasdaq (XRTX) and its Frankfurt listing (ANU).

XORTX, a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease, will announce the timing of the delisting in a separate press release.

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX) has appointed Mika Grasso, 28, as co-CEO responsible for finance and public markets, and says it aims to advance its lead gout program, XRx-026, toward marketing approval over the next 18 months.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has appointed Depesh Narotam, a financial services executive with more than 20 years of experience, to its board as an independent director effective July 27, 2026.

Board determines Narotam meets Nasdaq and Canadian independence standards

The board determined that Narotam, 43, is independent under applicable Nasdaq listing standards and Canadian securities laws. He also joins the board's Compensation, Governance and Nominating Committee.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) said board chairman Anthony Giovinazzo is stepping down from the board of directors, citing personal reasons and a wish to pursue other interests.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX) has rescinded a US$2.5 million investor relations agreement with IR Agency LLC and recovered the full fee. The company is postponing its marketing push while it exits the TSX Venture Exchange.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services, following completion of its voluntary delisting from the TSX Venture Exchange.

XORTX restores IR Agency LLC consulting agreement on previously disclosed terms

The new consulting agreement carries substantially the same terms the company disclosed in news releases dated May 19, 2026 and August 28, 2026. The source gives no fee, share-based compensation or contract-length figures for the renewed engagement.